Abstract
Concomitant chemoradiotherapy holds promise in the therapy of advanced head and neck cancer. We have previously reported on the combination of 5-fluorouracil, hydroxyurea, and concomitant chemoradiotherapy administered on an alternate-week basis. In this ongoing study, we are testing the feasibility of adding continuous-infusion paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) to this combination. Background information and early clinical data are presented.
Publication types
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, P.H.S.
-
Review
MeSH terms
-
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Clinical Trials as Topic
-
Combined Modality Therapy
-
Fluorouracil / administration & dosage
-
Head and Neck Neoplasms / drug therapy*
-
Head and Neck Neoplasms / radiotherapy*
-
Humans
-
Hydroxyurea / administration & dosage
-
Infusions, Intravenous
-
Paclitaxel / administration & dosage
Substances
-
Paclitaxel
-
Fluorouracil
-
Hydroxyurea